Business
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Information for Patients
About this update from Staar Surgical Company
[{"type":"text","content":"\nEVO Lenses Provide Visual Freedom from Contact Lenses and Glasses\n\nOver One Million EVO Lenses Have Already Been Implanted Worldwide\n\nInformation for Patients and Doctor Finder at DiscoverEVO.com\n\n LAKE FOREST, Calif.--(BUSINESS WIRE)--\nSTAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the EVO/EVO+ Visian® Implantable Collamer® Lens (“EVO”) for the correction of myopia and myopia with astigmatism. Myopia, which is also known as nearsightedness or the need for distance vision correction, is the most common vision disorder globally and its prevalence is rapidly growing.1 An estimated 100 million U.S. adults ages 21 to 45 who have myopia are potential candidates for EVO, a biocompatible implantable lens that corrects distance vision.2\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005207/en/EVO Visian ICL, Envision A Life Without Hesitation. (Graphic: Business Wire)\nSee Video, EVO Visian ICL, Envision A Life Without Hesitation: https://vimeo.com/646690200/bd1457636b\n\nSee Video, EVO Visian ICL Information and Animated Procedure: https://vimeo.com/646689696/1181db7c57\n\n\"Following FDA approval, prospective patients in the U.S. and their doctors may now consider EVO for achieving Visual Freedom from the limitations, ongoing maintenance and inconvenience associated with glasses and contact lenses,” said Caren Mason, President and CEO of STAAR Surgical. “Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again.3 The EVO lens is additive, provides excellent quality of vision day and night, does not cause dry eye syndrome and is removable by a doctor, if ever so desired.4,5,6 Sales of EVO lenses outside the U.S. increased 51% in 2021 and have more than doubled since 2018, which speaks to the increasing choice by patients and our surgeon partners for EVO as the premium and primary solution for refractive vision correction. Surgeons will be trained and certified for EVO, and begin implanting EVO in the coming days and weeks in select cities. Commercialization o...